Developing a bioanalytical assay for stromal cell therapies: an interview with Laura Deedigan, Orbsen Therapeutics
In this interview, Laura Deedigan (Orbsen Therapeutics) discusses the challenges in characterizing the purity of MSCs and why this is in important in cellular therapies.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.